Naiyer A. Rizvi

Naiyer Rizvi is a leading thoracic oncologist who has advanced precision immunotherapy approaches for lung cancer. His research established tumor mutational burden (TMB) as a predictive biomarker for checkpoint inhibitor response, fundamentally changing how patients are selected for immunotherapy. Rizvi continues to develop next-generation biomarkers and combination strategies.

Naiyer Rizvi是领先的胸腔肿瘤学家，他推进了肺癌的精准免疫治疗方法。他的研究确立了肿瘤突变负荷（TMB）作为检查点抑制剂反应的预测性生物标志物，从根本上改变了患者免疫治疗的选择方式。Rizvi继续开发下一代生物标志物和组合策略。